Nir Barzilai

Background

Nir Barzilai is an Israeli-American physician-scientist at the Albert Einstein College of Medicine in New York, known for his research on the genetics of exceptional human longevity and for leading efforts to test whether aging itself can be slowed with medicine. He directs the Institute for Aging Research at Einstein, where he has spent decades studying people who live to 100 in good health. His central argument is that aging is the largest shared risk factor for chronic disease and should be treated as a target in its own right, an approach sometimes called geroscienceTermGeroscienceThe field studying how aging mechanisms drive multiple chronic diseases and how targeting them might extend healthspan.In glossary →. He trained as a physician in Israel before moving to the United States to pursue research on metabolism and aging, and his 2020 book Age Later brought these ideas to a wide readership.

Longevity Genes Project

Barzilai's best-known research program is the Longevity Genes Project, a study of hundreds of Ashkenazi Jewish centenarians and their children. This population is relatively genetically uniform, which makes it easier to spot gene variants associated with long life. He and his colleagues found that many centenarians carry protective variants in genes affecting cholesterol metabolism, including changes in the CETP and APOC3 genes, linked to preserved cognition and cardiovascular health. A striking theme is that centenarians are often not especially virtuous in their habits; many smoked, drank, or were overweight yet still reached extreme age, which suggests their protection is largely genetic. Barzilai has argued that these longevity genes point toward biological pathways that drugs might one day imitate, and he later broadened the effort into a larger initiative studying families with unusual longevity.

The TAME trial

Barzilai is the principal architect of TAME, or Targeting Aging with Metformin, a proposed large, multicenter clinical trial. Metformin is a widely used, inexpensive diabetes drug with a long safety record, and observational data have hinted that people who take it may have lower rates of several age-related diseases. TAME is designed not to treat any single disease but to test whether metformin can delay the onset of a cluster of conditions, including heart disease, cancer, and dementia, in older adults. Its deeper purpose is regulatory, because aging is not recognized as a treatable condition, so no therapy can currently be approved to target it, and by using a composite outcome of multiple diseases TAME is intended to create a template showing that aging can be measured and slowed in a trial. The design has made TAME one of the most closely watched efforts in the field, even as it has faced challenges in securing funding, and whether metformin meaningfully slows aging in healthy people remains unproven.

Influence

Barzilai is a prominent voice for the view that treating aging can compress the period of late-life illness, a goal he shares with researchers such as Cynthia KenyonPersonCynthia KenyonMolecular biologist whose 1993 discovery that a single daf-2 gene mutation doubles the lifespan of the worm C. elegans reshaped the modern biology of aging.Person →. He connects the genetics of centenarians to the broader framework of the hallmarks of agingArticleHallmarks of AgingA shared framework that organizes aging into interconnected biological processes, giving longevity research a common map of what to measure and target.Read entry → and to the search for biomarkers of aging that could measure whether an intervention is working, and his work sits alongside other candidate approaches including rapamycin, caloric restriction, and newer metabolic drugs such as the GLP-1 receptor agonists. Through his writing and advocacy he has helped move the idea of targeting aging from the fringe toward mainstream biomedicine, carefully distinguishing the goal of extending healthy years from promises of radical life extension.

Related pages

What links here

No backlinks yet.